ERK Inhibitor Enhances Everolimus Efficacy through the Attenuation of dNTP Pools in Renal Cell Carcinoma

• Główni autorzy: Yun Zou (Autor), Wenzhi Li (Autor), Juan Zhou (Autor), Jin Zhang (Autor), Yiran Huang (Autor), Zhong Wang (Autor)
• Format: Książka
• Wydane: Elsevier, 2019-03-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

The clinical efficiency of everolimus, an mammalian target of rapamycin (mTOR) inhibitor, is palliative as sequential or second-line therapy for renal cell carcinoma (RCC). However, the limited response of everolimus in RCC remains uncertain. In the present study, everolimus-resistant RCC models wer...